Effects of GLP-1 on bone health in healthy volunteers
SHORT-term Effects of GLucagon-like Peptide One on BonE
This study is testing if a hormone called GLP-1 can improve bone health in healthy people by looking at how it affects bone growth and breakdown.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Odense University Hospital Academic / other |
| Locations | 1 site (Odense) |
| Trial ID | NCT06722560 on ClinicalTrials.gov |
What this trial studies
This study investigates the physiological effects of glucagon-like peptide 1 (GLP-1) on bone remodeling in healthy individuals. It aims to understand how GLP-1 influences bone formation and resorption, which are critical processes for maintaining bone health. Participants will receive either GLP-1 hormone or a placebo to assess the impact on bone metabolism, measured through specific biomarkers. The study seeks to clarify the role of gut hormones in bone health and their potential therapeutic implications.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy individuals without diabetes or significant metabolic disorders.
Not a fit: Patients with diabetes, high BMI, or conditions affecting bone metabolism are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new treatments for improving bone health and preventing osteoporosis.
How similar studies have performed: Previous studies have shown varying effects of GLP-1 on bone metabolism, indicating that this approach is promising but not yet fully established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy Exclusion Criteria: * Diabetes mellitus including prediabetes (Hb1Ac \>42 mmol/mol at baseline) * BMI \> 28 kg/m2 * Conditions and pharmaceutical treatments that influence bone metabolism (e.g., bone fractures \< 6 months, uncontrolled thyrotoxicosis, and severe renal impairment). * Pregnancy * Inability to complete all investigations or to provide informed consent
Where this trial is running
Odense
- Department of Endocrinology, University Hospital of Odense — Odense, Denmark (Recruiting)
Study contacts
- Study coordinator: Julie Bjerrelund, MD, PhD-student
- Email: julie.bjerrelund@rsyd.dk
- Phone: +65 411807
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.